gossypol has been researched along with Adenocarcinoma in 12 studies
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study has evaluated the chemopreventive effects of gossypol on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced gastric carcinogenesis and on human gastric adenocarcinoma (AGS) cell line." | 7.77 | In vitro and in vivo studies on antitumor effects of gossypol on human stomach adenocarcinoma (AGS) cell line and MNNG induced experimental gastric cancer. ( Gayathri, R; Gunassekaran, GR; Priya, DK; Sakthisekaran, D, 2011) |
| "The present study has evaluated the chemopreventive effects of gossypol on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced gastric carcinogenesis and on human gastric adenocarcinoma (AGS) cell line." | 3.77 | In vitro and in vivo studies on antitumor effects of gossypol on human stomach adenocarcinoma (AGS) cell line and MNNG induced experimental gastric cancer. ( Gayathri, R; Gunassekaran, GR; Priya, DK; Sakthisekaran, D, 2011) |
| "Patients with metastatic prostate cancer scheduled to start, or who had recently (within 6 weeks) initiated, ADT were enrolled." | 2.82 | A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. ( DiPaola, RS; Goodin, S; Hussain, M; Jeyamohan, C; Kaufman, HL; Liu, G; Mehnert, J; Stadler, WM; Stein, MN; Tereshchenko, IV, 2016) |
| "AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC)." | 2.77 | Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. ( Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA, 2012) |
| " Unlike trials with continuous daily dosing of AT-101, no cases of small bowel obstruction were reported." | 2.76 | Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. ( Holmlund, JT; Karaseva, NA; Leopold, L; Luft, AV; Orlov, SV; Popovych, O; Ready, N; Wood, BA, 2011) |
| "Further investigation of AT-101 in prostate cancer is warranted and trials combining AT-101 with androgen deprivation, as well as with docetaxel chemotherapy are ongoing." | 2.74 | An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. ( Brill, K; Kelly, WK; Leopold, L; Liu, G; Somer, B; Wilding, G, 2009) |
| " Here, we investigated the efficacy of AT-101 (R-(-)-gossypol acetic acid; a pan small molecule inhibitor of Bcl-2, Bcl-x(L), and Mcl-1) in combination with surgical castration to delay the onset of androgen-independent growth in vivo." | 1.34 | In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. ( Loberg, RD; McGregor, N; Pienta, KJ; Sargent, E; Ying, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, C | 1 |
| Song, Y | 1 |
| Li, P | 1 |
| Messeha, SS | 1 |
| Zarmouh, NO | 1 |
| Mendonca, P | 1 |
| Cotton, C | 1 |
| Soliman, KFA | 1 |
| Stein, MN | 1 |
| Hussain, M | 1 |
| Stadler, WM | 1 |
| Liu, G | 2 |
| Tereshchenko, IV | 1 |
| Goodin, S | 1 |
| Jeyamohan, C | 1 |
| Kaufman, HL | 1 |
| Mehnert, J | 1 |
| DiPaola, RS | 1 |
| Kelly, WK | 1 |
| Wilding, G | 1 |
| Leopold, L | 4 |
| Brill, K | 1 |
| Somer, B | 1 |
| Zhang, XQ | 1 |
| Huang, XF | 1 |
| Mu, SJ | 1 |
| An, QX | 1 |
| Xia, AJ | 1 |
| Chen, R | 1 |
| Wu, DC | 1 |
| Heist, RS | 1 |
| Fain, J | 1 |
| Chinnasami, B | 1 |
| Khan, W | 1 |
| Molina, JR | 1 |
| Sequist, LV | 1 |
| Temel, JS | 1 |
| Fidias, P | 1 |
| Brainerd, V | 1 |
| Lynch, TJ | 1 |
| Ready, N | 1 |
| Karaseva, NA | 1 |
| Orlov, SV | 1 |
| Luft, AV | 1 |
| Popovych, O | 1 |
| Holmlund, JT | 2 |
| Wood, BA | 2 |
| Gunassekaran, GR | 1 |
| Priya, DK | 1 |
| Gayathri, R | 1 |
| Sakthisekaran, D | 1 |
| Sonpavde, G | 1 |
| Matveev, V | 1 |
| Burke, JM | 1 |
| Caton, JR | 1 |
| Fleming, MT | 1 |
| Hutson, TE | 1 |
| Galsky, MD | 1 |
| Berry, WR | 1 |
| Karlov, P | 1 |
| Brookes, M | 1 |
| Zhang, M | 1 |
| Liu, H | 1 |
| Tian, Z | 1 |
| Griffith, BN | 1 |
| Ji, M | 1 |
| Li, QQ | 1 |
| Loberg, RD | 1 |
| McGregor, N | 1 |
| Ying, C | 1 |
| Sargent, E | 1 |
| Pienta, KJ | 1 |
| Rekha, GK | 1 |
| Sladek, NE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression[NCT01977209] | Phase 3 | 204 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for gossypol and Adenocarcinoma
| Article | Year |
|---|---|
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy | 2016 |
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Co | 2009 |
Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Re | 2010 |
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Prot | 2011 |
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2012 |
7 other studies available for gossypol and Adenocarcinoma
| Article | Year |
|---|---|
MCL1 regulates cell death, tumor growth and chemosensitivity to sabutoclax in ovarian adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2020 |
Molecular mechanism of gossypol mediating CCL2 and IL‑8 attenuation in triple‑negative breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chemokine CCL2; Female; Gene Expression Reg | 2020 |
Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell | 2010 |
In vitro and in vivo studies on antitumor effects of gossypol on human stomach adenocarcinoma (AGS) cell line and MNNG induced experimental gastric cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2011 |
Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways.
Topics: Adenocarcinoma; Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Apoptosis Reg | 2007 |
In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Combined Modality T | 2007 |
Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase; Antineoplastic Agents, Alkylating; Breast Neoplasms; Catecho | 1997 |